Document Fragment View
Fragment Information
Showing contexts for: x-ray diffraction in Daewoong Pharmaceutical Co. Ltd. & Anr vs Controller General Of Patents Designs ... on 23 March, 2026Matching Fragments
7. The claim submitted by the appellant to the patent office with the post hearing written submissions on 14.10.2021 is reproduced as follows:
"We claim:
1. A crystalline form of a compound of the following Formula c28:
[Formula c28] wherein the crystalline form has an X-ray diffraction (XRD) spectrum which includes peaks at diffraction angles (2 θ) of 6.2°±0.2°, 7.2°±0.2°,